Abstract
Nonalcoholic steatohepatitis (NASH) or metabolic dysfunction-associated steatohepatitis (MASH) is a long-term chronic liver disease condition that stems from nonalcoholic fatty liver disease (NAFLD) and results from multiple factors, including lifestyle, metabolic dysfunction, and genetic predisposition. The increasing prevalence of NAFLD in the global population is expected to reach over 35% by 2030. It thus has become a significant public health concern because of its association with metabolic syndrome, cardiovascular diseases, diabetes mellitus, and hepatocellular carcinoma. Therefore, early diagnosis is crucial to avoid further liver disease complications and to provide early and effective patient care. Though there are diagnostic measures available for NASH/MASH detection, like biopsy and serological assays, these are mostly invasive and do not provide the complete picture of the liver condition. Point-of-care diagnostics like biosensors can help overcome these limitations by allowing for a rapid, inexpensive, and more straightforward diagnostic method that also aligns with the present global health needs. Moreover, integrating artificial intelligence and machine learning approaches for automated analysis alongside real-time cloud-based reporting and telehealth interfaces can potentially aid in expanding the utility of these systems into integrated diagnostic systems. Through this review, we aim to address the interplay of technological innovation, public health significance, and implementation barriers in advancing biosensor diagnostics for effective and reliable detection of NASH/MASH for better liver health.